VNP 489
Latest Information Update: 21 Jul 2010
At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 09 Feb 2005 Phase-I clinical trials in Hypertension in USA (unspecified route)